TrialJNCI cancer spectrum2026

Sequential chemo-durvalumab, reduced-dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial).

Francesco Agustoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.